Jens Eckstein has been named president of SR One, GSK's independent healthcare venture organisation, effective 1 October. Mr Eckstein will replace Christoph Westphal who is leaving GSK at the end of the year to focus on external business interests, including the Longwood Founder's Fund in which GSK is an investor. Mr Eckstein has served at TVM Capital since 2004, currently as venture partner and entrepreneur-in-residence. He is also currently interim CEO and president of SelectX Pharmaceuticals.